Current Research Studies
SC-2043 WUC007-03: A PHASE 2 STUDY OF WU-CART-007, AN ANTI-CD7 ALLOGENEIC CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA
SC-2043 WUC007-03
What is the goal of the study?
WU-CART-007 is a cluster of differentiation (CD)7-directed, genetically modified, allogeneic, fratricide-resistant chimeric antigen receptor (CAR) T-cell product for the treatment of CD7+ve (CD7-positive) hematologic malignancies. To manufacture WU-CART-007 drug product (DP), T cells from healthy donors are edited to delete the genes that express CD7 and T-cell receptor alpha constant (TRAC), transduced with a second-generation CAR targeting CD7, expanded, purified to remove residual T-cell receptor (TCR) ⍺/β+ve cells, formulated and cryopreserved.
Who can participate in the study?
Please contact the study team listed below to learn more.